Yesterday, Aug. 31, 2015, 70 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $889.92 to $16,133,353.20.

Highlighted Stocks Traded by Insiders:

MasTec (MTZ) - FREE Research Report

Johnson Julia L, who is Director at MasTec, bought 15,000 shares at $15.86 on Aug. 31, 2015. Following this transaction, the Director owned 70,372 shares meaning that the stake was boosted by 27.09% with the 15,000-share transaction.

The shares most recently traded at $16.09, up $0.23, or 1.41% since the insider transaction. Historical insider transactions for MasTec go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 11,324
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 11,324
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 11,324

The average volume for MasTec has been 1.3 million shares per day over the past 30 days. MasTec has a market cap of $1.3 billion and is part of the industrial goods sector and materials & construction industry. Shares are down 26.76% year-to-date as of the close of trading on Monday.

MasTec, Inc., an infrastructure construction company, provides engineering, building, installation, maintenance, and upgrade services for communications, energy, and utility infrastructure in the United States and internationally. The company has a P/E ratio of 20.6. Currently, there are 7 analysts who rate MasTec a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MTZ - FREE

TheStreet Quant Ratings rates MasTec as a hold. The company's strongest point has been its a solid financial position based on a variety of debt and liquidity measures that we have looked at. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income. Get the full MasTec Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AXT (AXTI) - FREE Research Report

Zhang Davis, who is Shareholder at AXT, sold 20,635 shares at $2.21 on Aug. 31, 2015. Following this transaction, the Shareholder owned 202,488 shares meaning that the stake was reduced by 9.25% with the 20,635-share transaction.

The shares most recently traded at $2.17, down $0.04, or 1.65% since the insider transaction. Historical insider transactions for AXT go as follows:

  • 4-Week # shares sold: 22,350
  • 12-Week # shares sold: 22,350
  • 24-Week # shares sold: 22,350

The average volume for AXT has been 52,500 shares per day over the past 30 days. AXT has a market cap of $71.8 million and is part of the technology sector and electronics industry. Shares are down 21.79% year-to-date as of the close of trading on Monday.

AXT, Inc. designs, develops, manufactures, and distributes compound and single element semiconductor substrates. The company manufactures its semiconductor substrates using its proprietary vertical gradient freeze technology. Currently, there is 1 analyst who rates AXT a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AXTI - FREE

TheStreet Quant Ratings rates AXT as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and poor profit margins. Get the full AXT Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cepheid (CPHD) - FREE Research Report

Farrell Peter V., who is EVP, Worldwide Commercial Ops at Cepheid, sold 1,577 shares at $48.67 on Aug. 31, 2015. Following this transaction, the EVP, Worldwide Commercial Ops owned 25,738 shares meaning that the stake was reduced by 5.77% with the 1,577-share transaction.

The shares most recently traded at $48.03, down $0.64, or 1.34% since the insider transaction. Historical insider transactions for Cepheid go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 7,048
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 7,223
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 8,250

The average volume for Cepheid has been 712,600 shares per day over the past 30 days. Cepheid has a market cap of $3.6 billion and is part of the technology sector and electronics industry. Shares are down 9.97% year-to-date as of the close of trading on Monday.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. Currently, there are 12 analysts who rate Cepheid a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPHD - FREE

TheStreet Quant Ratings rates Cepheid as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Cepheid Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.